Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
- 8 August 2018
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 32 (9) , 2087-2090
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (German Research Foundation) (KO2155/6-1)
- José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) (DJCLS 16 R/2017)
This publication has 11 references indexed in Scilit:
- Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenitaLeukemia, 2018
- A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiationLeukemia, 2016
- Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionJournal of Hematology & Oncology, 2016
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic TransformationCancer Discovery, 2016
- Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasmsBlood, 2016
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutantsBlood, 2016
- MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signalingLeukemia, 2014
- SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2New England Journal of Medicine, 2013
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent MechanismJournal of Investigative Dermatology, 2012